Loading...

lov2laf's Recent CancerCompass Activity

  • lov2laf has replied to a post on the message board

    www.mpdsupport.org, there is hope, new drugs in trials, itching can be controlled, I went misdiagnosed ten years, quite common. We have rare diseases about 1 per 100,000. Go see one of these MPD specialists, www.mpd-rc.org research hospitals, local community oncologists mostly deal with solid tumors. Get him on an SSRI if he is depressed, depression adversely affects morbidity and mortality. Caution with cachexia, dr...

    January 13, 2015 view post
    • lov2laf has replied to a post on the message board

      Try www.mpdsupport.org and on Facebook https://www.facebook.com/groups/375525335856981/ Try http://www.mpd-oz.org/ I have an itch information file for those of us with an MPD. Email me at roberttollen at gmail dot com. 

      view post
      • lov2laf has replied to a post on the message board

        Hi, I run past 18 years http://bit.ly/subscribeMPDsupport Many advanced MF patients are pleased with Jakafi, it treats symptoms but not the underlying disease. Beware if it stops working, it can be a dangerous time. Figure he will see dramatic improvement in short order, a month or so.  Adverse effects of ruxolitinib treatment discontinuation in MPNshttp://bit.ly/u9PGAT Robert

        view post
        • lov2laf has created a new message board discussion

          http://listserv.icors.org/SCRIPTS/WA-ICORS.EXE?A0=MPDSUPPORT or  http://bit.ly/subscribeMPDsupport Main web site > www.mpdsupport.org A myeloproliferative disease mailing list focusing on polycythemia vera, essential thrombocythemia, agnogenic myeloid metaplasia, chronic myelogenous leukemia, and myelofibrosis. Anyone - patient, family member, or health professional, is welcome to join.

          view discussion
          Loading...
          Load more activity
          Loading more activity

          About lov2laf

          Survivor
          Other Cancer

          We care about your feedback. Let us know how we can improve your CancerCompass experience.